Buy a Home HIV Test

Welcome

Human immunodeficiency virus (HIV) attacks the immune system, the body's defense against infection. HIV is commonly transmitted during sex or intravenous (IV) drug use. There are an estimated 40 million people living in the world with HIV. Currently there is no cure, but early detection and treatment can help people live much longer. This service would be good for you if you think you are able to cope with being told the results without a specialist present. You should always consider a follow-up test at a clinic.

It is very important that you wait three and a half months after possible infection before testing for HIV. This is because any test is unlikely to pick up signs of HIV infection in the first 14 weeks of infection. For more information on HIV, please visit The Body.

Our service is totally confidential. We won't inform anyone of any details. You can buy a home Rapid Anti-HIV (1&2) Test here and we will deliver it via 1st class post. The test kits sold here are 99.9% accurate. You will know the results within 10 minutes. The tests screen and detect HIV-1 & HIV-2 antibodies in a blood sample. The presence of HIV antibodies indicates the presence of the HIV virus.

The tests have been approved by USAID. Please click here to view the USAID List of Approved HIV/AIDS Rapid Test Kits.

Latest News

Living Proof BCAP celebrates 25 years of supporting HIV-positive people and fighting stigma

BOULDER — Barb Cardell wore “an ugly man’s watch” with eight alarm settings after she was diagnosed in 1993 with human immunodeficiency virus.

Now, though she swallows 60 pills a day to stay healthy, she needs no reminders. Cardell long ago memorized her medication schedule and all of its empty-stomach or full-stomach requirements.

But the stigma surrounding the infection she got from an HIV-infected boyfriend in 1991 still haunts her.

Though once an ambitious executive chef, she will never cook professionally again.

“People are afraid of eating that food, though that’s not how HIV spreads,” said Cardell, 46.

The Boulder County AIDS Project, which this year marks its 25th anniversary, faces the same challenge as it serves HIV-positive men, women and children living in Boulder, Broomfield, Clear Creek and Gilpin counties.

It offers free and confidential HIV testing, case management, medical care access, financial assistance, food bank resources, support groups and more.

Yet BCAP wants the Longmont branch, which this month relocated to 515 Kimbark St., to maintain a low profile.

“We have people who haven’t even told their sister, who they live with, because the stigma is so strong,” said Dan Hanley, BCAP’s development director. “Some of that stigma comes from homophobia. … But we’re in Longmont because there is a need.”

Cardell, a heterosexual woman who married in 1993 just before she was diagnosed, first volunteered at BCAP in 1994 after moving from Madison to Boulder. She remembers volunteers lighting a candle by the front desk in the Boulder home office whenever a client died.

Stigma caused some families to submit nothing more than the first initial of the late client’s name and the date of death to post by the flame.

“And this is at an AIDS organization,” Cardell said.

Volunteers from BCAP’s earliest years nevertheless appreciate progress between now and when the AIDS crisis first hit in the early 1980s.

For instance, burning the bed sheets crossed Neil Fishman’s mind after a buddy in California stricken with AIDS visited a mutual friend in Boulder.

“We didn’t know anything. We thought you might get it from toilet seats or door knobs. Scientists had not yet even isolated the virus then,” Fishman, 54, said.

HIV, the virus that causes the deadly AIDS, passes from an infected person to another person through blood, semen, vaginal fluids and breast milk.

Fishman, a Boulder scientist who served from 1987 to 1990 as BCAP’s third president, recalled how two volunteers launched what is now known as BCAP in 1985. They incorporated the nonprofit organization as the Boulder County Health Network to avoid using the AIDS acronym in the return address on mailings.

Though that euphemistic name eventually changed, BCAP managed to attract more clients and volunteers outside the gay community.

Bonnie Crumpacker, a wife and mother of four, volunteered in 1987 as Fishman’s vice president after she heard then-Colorado Rep. David Skaggs fielding complaints from gay men in Boulder. They reported housing and medical care discrimination related to their homosexual or bisexual orientation.

“(Supporting BCAP) was an act of bravery. A lot of people hate gay people,” the Boulder resident said. “But at some point, people began to realize it could be their child, certainly. … I knew young men whose parents just couldn’t adjust. I found that hard, and then they would come around for the funeral.”

Before the 1996 debut of protease inhibitors — powerful drug cocktails to slow the spread of HIV — AIDS (the infection’s end-stage immune system crash) ranked as the leading cause of death among those between ages 25 and 44 in the United States, the Centers for Disease Control and Prevention reports.

Crumpacker, 83, remembers the peculiarity of visiting so many sick young men — one of whom died in her presence — during her BCAP tenure.

Today, AIDS is the sixth highest cause of death for that age category.

The majority of new annual HIV cases in the U.S. still stem from men who have sex with men. But heterosexual contact accounts for 31 percent of annual new infections, according to the CDC.

That statistic and her personal experience pushed Cardell to serve beyond her volunteer roles over the years as BCAP’s bookkeeper, board member and client chauffeur.

“I went to BCAP and said, ‘You guys need a woman to tell your story.’ And they said, ‘Well, we had one, and she died. So it looks like it’s you,’” she said.

Now, Cardell speaks publicly on behalf of BCAP to prevent disease transmission, encourage early treatment and break stereotypes.

“(Adults) want to hear that you slept with a million people or used injection drugs. They want you to be so different that they don’t have to worry about it,” she said. “But kids say, ‘Now I know that you’re just like everyone else. You just have to try harder to live.’”

HIV testing centre craves for kits and patients

BANGALORE: The HIV testing centre at Bruhat Bangalore Mahanagara Palike (BBMP) Maternity Home at Palace Guttahalli needs an immediate attention. It neither has the requited staff nor HIV testing kits.
The State Government and the Bruhat Bangalore Mahanagara Palike have been spending lot of money to create awareness among the public on HIV/AIDS. Many voluntary counselling and testing centres (VCTCs) were opened at Government and BBMP Hospitals to test HIV cases. However, there is nothing to revel about the facilities available at the VCTC situated at the BBMP Maternity Home.
Since the HIV tests are not done on daily basis, people have to wait for a week to undergo HIV test. “I have to look after two VCTCs. I am on a deputation to this VCTC,’’ says a counsellor on anonymity.
The other problem at this voluntary counselling and testing centre is the acute shortage for HIV test kits. “We do not have the HIV test kits here. The higher authorities have promised to supply the HIV test kits. We hope they will make arrangements to supply HIV test kits,’’ said another employee at the VCTC.
Saroja Putran, president of Karnataka Network for People Living with HIV/AIDS (KNP+) , said that lack of HIV test kits and shortage of staff would create a wrong impression among the people who want to visit these VCTCs.
“I know that number of staff members depends on the number of people visit a voluntary counselling and testing centre. However, it is advisable to appoint sufficient number of staff at the VCTC for the benefit of people who want to consult counsellors or undergo HIV test voluntarily,’’ said Saroja.
Meanwhile, Dr Prakash, Additional Director, Karnataka State Acute Immuno Deficiency Syndrome (AIDS) Prevention Society (KSAPS) has assured to look into the matter.
“I will ask the employees concerned to provide details on the voluntary counselling and testing centre at the Bruhat Bangalore Mahanagara Palike Maternity Home,’’ said Dr Prakash.

FIOCRUZ Receives Regulatory Approval to Market Chembio DPP(R) HIV 1/2 Confirmatory Test in Brazil

MEDFORD, NY, Sep 23, 2010 (MARKETWIRE via COMTEX) — Chembio Diagnostics, Inc. (CEMI 0.24, -0.01, -4.08%) , which develops, manufactures, markets and licenses point-of-care diagnostic tests, has been notified that Bio-Manguinhos, a division of the Oswaldo Cruz Foundation of Brazil (”FIOCRUZ”), has received regulatory approval from Brazil’s National Health Surveillance Agency (”ANVISA”) to market Chembio’s Dual Path Platform (DPP(R)) HIV 1/2 Confirmatory rapid test for use with whole blood, serum or plasma samples. The approval triggers a $225,000 initial payment to Chembio.

FIOCRUZ (www.fiocruz.br) is a world-renowned public health organization affiliated with the Brazilian Ministry of Health and is the Ministry’s leading supplier for therapeutics, vaccines and diagnostic tests dedicated to public health. FIOCRUZ has entered collaborations with some of the world’s leading biotechnology companies in fulfillment of its mission.

This is the second DPP(R) test developed by Chembio to receive regulatory approval in Brazil in the last three months. In June, the Company reported approval of its DPP(R) oral fluid HIV 1/2 screening test by ANVISA. This is however the first DPP(R) multiplex test employing Chembio’s patented Dual Path Platform to received regulatory approval. One of the unique features of DPP(R) is its enabling of multiple parameter tests to be developed. The confirmatory test uniquely detects five different strains of HIV in a single point-of-care device.

During 2008 Chembio signed four agreements with FIOCRUZ relating to products based on the Company’s DPP(R) technology, including this HIV confirmatory test. Previous to that, in 2004, Chembio and FIOCRUZ entered a successful collaboration pertaining to Chembio’s HIV 1/2 STAT-PAK(R). Under the DPP(R) HIV 1/2 Confirmatory rapid test agreement with FIOCRUZ, a technology transfer to FIOCRUZ for this product is contracted for, which is anticipated to occur in stages over a three-year period. During that period the agreement provides for minimum sales by Chembio to FIOCRUZ for this product and related components of approximately $4.7 million. Thereafter, it is anticipated that the technology transfer process will be completed. The agreement for the previously approved oral fluid HIV test, combined with this agreement pertaining to the HIV confirmatory test, represent combined potential aggregate sales of at least $13.5 million based on the minimum sales required under these agreements in order to complete the technology transfer.

Lawrence Siebert, Chembio’s Chief Executive Officer, said, “This product approval is an important milestone relating to our DPP(R) technology, as it very clearly demonstrates the capabilities of our platform, replacing time-consuming, laboratory-dependent tests with products that can provide critical information at the point of care.”

About Chembio Diagnostics Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $7 billion point-of-care testing market. Chembio’s two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere North America, Inc. (formerly Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK(R) line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP(R)) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP(R). Headquartered in Medford, NY, with approximately 100 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For more information, please visit: www.chembio.com.

Forward-Looking Statements Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed a review or audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio’s ability to obtain additional financing, to obtain regulatory approvals in a timely manner and the demand for Chembio’s products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio’s success are more fully disclosed in Chembio’s most recent public filings with the U.S. Securities and Exchange Commission.